Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: February 09, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 140 million |
|
Revenue Forecast in 2030 |
US$ 205 million |
|
CAGR |
4.3% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Method, Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global small intestinal bacterial overgrowth (SIBO) diagnostics market was valued at US$ 140 million in 2021 and is expected to register a revenue CAGR of 4.3% to reach US$ 205 million by 2030.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Fundamentals
Small intestinal bacterial overgrowth, or SIBO, is an imbalance of the gut bacteria necessary for normal digestion. Unpleasant symptoms, such as gas and diarrhea, can result from the small intestine being overrun by the incorrect bacteria or in excess numbers. Additionally, it may prevent an individual from properly digesting and absorbing nutrients from food.
SIBO affects up to 80% of individuals with irritable bowel syndrome (IBS), states Cleveland Clinic. Physicians believe that around US$ 205 million cases of SIBO are frequently undiagnosed. SIBO symptoms can resemble many gastrointestinal conditions. Patients with SIBO experience abdominal pain, nausea, distention, bloating, gas, diarrhea, and constipation. Treatment of SIBO addresses overgrowth, SIBO complications, and its underlying cause.
Non-invasive tests for SIBO detect the quantities of hydrogen and/or methane in breath to detect gut bacteria that produce gas. Levels may indicate an abundance of bacteria at higher than a specific threshold. Healthcare providers may advise additional testing, such as blood tests for vitamin and blood protein deficits, to look for indicators of the causes and complications of SIBO. A stool test is used to examine bile acids or undigested fat. Nutritional support and supplementation are highly important in treating SIBO. A strict, short-term diet is recommended to control symptoms of SIBO, followed by a modified long-term diet plan to replace nutrition and control bacterial overgrowth.
[8575756]
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Dynamics
An increasing trend of consuming processed food in daily life can lead to SIBO. This is because processed foods often contain added sugars and starches, which can cause an imbalance of bacteria in the gut, leading to an overgrowth of certain bacteria. Additionally, processed foods often contain additives and preservatives, which can cause an imbalance in the pH of the gut. Therefore, increased consumption of processed foods can lead to SIBO, which in turn, is expected to drive revenue growth in the global market.
During the forecast period, the small intestinal bacterial overgrowth (SIBO) diagnostics market is anticipated to register revenue growth at a high CAGR, driven by high incidences of SIBO, mostly observed in diabetic patients and people with prior digestive issues. SIBO is common in diabetic patients, particularly those with T2DM, and diabetic peripheral neuropathy. Diabetes complications and the severity of T2DM have been linked to SIBO. According to NCBI, diabetes is considered a predisposing factor for developing SIBO, particularly in patients with jejunal aspirate culture diagnoses or those from Western ethnicities.
The link between SIBO and common bowel symptoms is expected to fuel revenue growth in the small intestinal bacterial overgrowth (SIBO) market size. With common bowel symptoms, such as persistent diarrhea, bloating, abdominal distention, and irritable bowel syndrome, the diagnosis of SIBO has increased significantly. A 2020 meta-analysis of 25 case-control studies involving 3,192 IBS patients and 3,320 controls provided information on the association between SIBO and IBS. The results showed that the prevalence of SIBO in patients with IBS was 31.0%. IBS and SIBO share many common symptoms. However, more studies and research are needed to study the link between them.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Ecosystem
The global small intestinal bacterial overgrowth (SIBO) diagnostics market is segmented based on three perspectives: diagnosis, type, and region.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market by Diagnosis
[345465]
Based on the diagnosis, the global small intestinal bacterial overgrowth (SIBO) diagnostics market has been segmented into breath testing, malabsorption tests, small intestine aspirate and fluid culture tests, blood tests, and others.
The benefits of breath testing, such as being a non-invasive procedure, make it one of the most demanding testing procedures among SIBO diagnostics. SIBO breath test is further sub-segmented into xylose breath, hydrogen breath test, and glycocholic acid breath. Among the different breath tests, the hydrogen breath test is highly preferred. It is the simplest, least invasive, and most accessible diagnostic method. The most common substrates used in hydrogen breath testing are carbohydrates, such as lactulose and glucose, with glucose possibly offering a higher level of testing accuracy.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market by Type
Based on the type, the global small intestinal bacterial overgrowth (SIBO) diagnostics market is segmented into hydrogen-predominant SIBO, methane-predominant SIBO, and recurrent SIBO.
The hydrogen-predominant SIBO segment dominates the global market. Hydrogen-predominant SIBO is one of the most common digestive disorders. This is because the hydrogen produced by the bacteria in the small intestine is not efficiently absorbed. This can lead to the fermentation of food particles and the production of gas, which can cause bloating and discomfort. SIBO can also cause nutrient deficiencies due to the inability to absorb essential vitamins and minerals. In addition, SIBO can cause a decrease in the absorption of fat, leading to malabsorption and weight loss. Treatment typically involves antibiotics and dietary modifications to reduce the bacterial load in the small intestine.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market by Region
Based on region, the global small intestinal bacterial overgrowth (SIBO) diagnostics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounts for the majority of the market revenue share. This is attributed to a combination of factors, such as increased antibiotic usage, changes in diet, and a rise in stress levels of people from developed and emerging economies. Additionally, the widespread prevalence of digestive disorders, such as irritable bowel syndrome (IBS), could contribute to the rise in SIBO cases.
The market Asia Pacific is anticipated to register growth with a high revenue CAGR in the coming years. This is attributed to improving healthcare standards in the region. Rising awareness of innovative diagnostic processes is also fueling revenue growth in the regional market. Moreover, the region has a high number of patients with gastrointestinal issues.
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Competitive Landscape
The prominent players operating in the global small intestinal bacterial overgrowth (SIBO) diagnostics market are:
Small Intestinal Bacterial Overgrowth (SIBO) Diagnostics Market Strategic Developments
The global small intestinal bacterial overgrowth (SIBO) diagnostics market is expected to register growth at a revenue CAGR of 4.3% during the forecast period.
Genova Diagnostics, SIBO Diagnostics, Commonwealth Diagnostics International, Aerodiagnostics, LLC, and Pivotal Diagnostics are among the top market players.
The breath testing segment dominates the global small intestinal bacterial overgrowth (SIBO) diagnostics market in terms of indication.
North America is expected to register the highest revenue growth in the small intestinal bacterial overgrowth (SIBO) diagnostics market during the forecast period.
The global small intestinal bacterial overgrowth (SIBO) diagnostics market was valued at 411 million in 2021.
*Insights on financial performance are subject to availability of the information in the public domain